Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-3.14805Keywords:
breast cancer, miRNA, resistanceAbstract
Summary. Aim: To identify the association of serum miRNAs with neoadjuvant polychemotherapy response in patients with breast cancer of luminal A and B subtypes. Materials and Methods: We analyzed the expression levels of circulating miR-21, -155, -182, -373, -199a, -205, -375 in serum of 182 breast cancer patients using real-time polymerase chain reaction. Each case was characterized by TMN criteria using morphological and immunohistochemical analyses. Results: Serum levels of miR-205 and -375 are associated with the response of luminal A tumors and miR-205 and -21 with the response of luminal B tumors to neoadjuvant polychemotherapy in fluorouracil + doxorubicin + cyclophosphamide and doxorubicin + cyclophosphamide regimens. In addition, we found correlation of miR-155, -182, -199a, -375 with 3-year relapse-free survival of patients. Based on the obtained data, we developed innovative prognostic and predictive panels to assess the drug sensitivity of tumors and lower the risk of breast cancer recurrence, which would significantly improve the treatment outcomes and the quality of life of patients. Conclusions: Serum levels of miR-155, -182, -199a, -205, -375 can be used as predictive and prognostic panel for monitoring BC course in Ukrainian population.
References
Larrea E, Sole C, Manterola L, et al. New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci 2016; 17: 627. doi: 10.3390/ijms17050627
Chekhun VF, Lukianova NY, Borikun TV, et al. The clinical significance of tumor mir-122,-155,-182, and -200b expression in patients with breast cancer. Science Innovation 2017; 13: 63–9 (in Ukrainian).
Chekhun VF, Borodai NV, Yurchenko OV. MiRNAs and cancer process. Onkologiya 2012; 15: 136–40 (in Russian).
Lekka E, Hall J. Noncoding RNAs in disease; FEBS Lett 2018; 592: 2884–900.
Chekhun VF, Borikun TV, Lukianova NY. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics. Exp Oncol 2016; 38: 26–30.
Chekhun VF. MicroRNAs are a key factor in the globalization of tumor-host relationships. Exp Oncol 2019; 41: 188–94.
Frixa T, Donzelli S, Blandino G. Oncogenic microRNAs: key players in malignant transformation. Cancers 2015; 7: 2466–85.
Baranwal S, Alahari SK. miRNA control of tumor cell invasion and metastasis. Int J Cancer 2010; 126: 1283–90.
Jiao X, Qian X, Wu L, et al. microRNA: The impact on cancer stemness and therapeutic resistance. Cells 2020; 9: 8. doi: 10.3390/cells9010008
Chekhun VF, Lukianova NY, Borikun TV, et al. Artemisinin modulating effect on human breast cancer cell lines with different sensitivity to cytostatics. Exp Oncol 2017; 39: 25–9.
Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev 2015; 81: 75–93.
Zadvornyi TV, Lukianova NY, Borikun TV, Chekhun VF. Effects of exogenous lactoferrin on phenotypic profile and invasiveness of human prostate cancer cells (DU145 and LNCaP) in vitro. Exp Oncol 2018; 40: 184–9.
Nakamura K, Sawada K, Yoshimura A, et al. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer 2016; 15: 48.
Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Science 2010; 101: 2087–92.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
Liu Y, Zhang Y, Li Q, et al. MiRNAs predict the prognosis of patients with triple negative breast cancer: a meta-analysis. PloS One 2017; 12: 1.
Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer gene therapy 2010; 17: 523–31.
Bondar OV, Malanchenko IL. The role of neoadjuvant polychemotherapy in the complex treatment of patients with locally advanced breast cancer. Odessa Med J 2017; 2: 40–3 (In Ukrainian).
https://patents. google.com/?q=microrna+breast+cancer+circulating&oq=microrna+breast+cancer+circulating
Zhao R, Wu J, Jia W, et al. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 2011; 34: 675–80.
Wang XX, Ye FG, Zhang J, et al. Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2. Cancer Manag Res 2018; 10: 4393–400.
Li Q, Liu M, Ma F, et al. Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS One 2014; 9: e104870.
Wang H, Tan G, Dong L, et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PloS one 2012; 7: e34210.
Shao B, Wang X, Zhang L, et al. Plasma microRNAs predict chemoresistance in patients with metastatic breast cancer. Technol Cancer Res Treat 2019; 18: 1533033819828709.
Aushev VN, Lee E, Zhu J, et al. Novel predictors of breast cancer survival derived from miRNA activity analysis. Clin Cancer Res 2018; 24: 581–91.
Lukianova NY, Borikun TV, Chekhun VF. Tumor microenvironment-derived miRNAs as prognostic markers of breast cancer. Exp Oncol 2019; 41: 242–7.
Gao J, Zhang Q, Xu J, et al. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res 2013; 25: 743–8.
Sun Y, Wang M, Lin G, et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PloS One 2012; 7: 1.
Wang PY, Gong HT, Li BF, et al. Higher expression of circulating miR‑182 as a novel biomarker for breast cancer. Oncol Lett 2012; 6: 1681–6.
Eichelser C, Flesch-Janys D, Chang-Claude J, et al. Deregulated serum concentrations of circulating cell–free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem 2013; 59: 1489–96.
Zhang L, Xu Y, Jin X, et al. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer. Breast Cancer Res Treat 2015; 154: 423–34.
Liu J, Mao Q, Liu Y, et al. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res 2013: 25: 46–54.
Papadaki C, Stoupis G, Tsalikis L, et al. Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer. Oncotarget 2019: 10: 966–81.
Han JG, Jiang YD, Zhang CH, et al. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res 2017; 92: 55–66.
Li Q, Liu M, Ma F, et al. Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS One 2014; 9: 8.
Liu B, Su F, Chen M, et al. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer. Hum Pathol 2017; 64: 44–52.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
